Oncology Central

State-of-the art advances in fertility preservation for the male cancer patient


In an era in which 80% of children and young adolescents who are diagnosed with cancer will survive and achieve cure, male fertility preservation is no longer considered a luxury, but a part of the therapeutic intervention and the standard of care. According to the American Society of Clinical Oncology (ASCO) guidelines 2013, as a component of patient education and an informed consent before cancer therapy, healthcare providers should address the gonadotoxic effect of cancer treatments, and discuss fertility preservation methods with patients prior to the onset of therapy [1].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.